Effectiveness of Nucleotide Use in Neurological Practice

Nemish I.L.

Main
Publications
Effectiveness of Nucleotide Use in Neurological Practice

March 27, 2025

Neurology and Psychiatry

Nemish I.L.

УДК: 616.85

DOI: 10.32471/umj.1680-3051.264366

Keywords :

neuropathic pain,

neuropathy,

nucleotides,

peripheral neuropathy

Specialities :

Neurology and Psychiatry

Resume

Peripheral neuropathy (PN) is a common neurological disorder characterized by progressive nerve fiber damage. The etiology of PN includes metabolic disorders (such as diabetes mellitus), B-group vitamins deficiencies, infectious, toxic, and autoimmune factors. Despite the diversity of etiological factors, PN treatment remains primarily symptomatic, with therapeutic strategies aimed at slowing disease progression, reducing pain, and stimulating nerve fiber regeneration. Nucleotides, particularly uridine phosphate, play a key role in nerve tissue regeneration by stimulating neurotrophic factor synthesis, promoting myelin sheath restoration, and exerting anti-inflammatory effects, which collectively contribute to effective neuropathic pain relief. In Ukraine, an effective combination of nucleotides, vitamin B12, and folic acid is available in oral capsule form under the trade name Neuriston^®. As part of comprehensive therapy, this formulation supports nerve system recovery and is indicated for metabolic, traumatic, toxic, and infectious neuropathies. Clinical studies have confirmed that Neuriston^®, when used in combination therapy, reduces pain syndrome, improves motor function, and may help decrease the need for nonsteroidal anti-inflammatory drugs in patients with PN. Thus, Neuriston^® is a modern and effective solution for patients with various forms of PN.

References

1. Rodriguez-Saldana J., Mijangos J.H.S., Hancock C.N. et al. (2024) Prevalence and disease burden of peripheral neuropathy in the general population in Mexico city: a cross-sectional epidemiological study. Cur. Med. Res. Opin., 40(6): 977–987.
2. International Diabetes Federation (2021) IDF diabetes atlas. 10th ed. Brussels, Belgium: International Diabetes Federation.
3. Gherlan G. (2018) Infectious neuropathies. Romanian J. Inf. Dis., 21(1): 6–11.
4. Dong Y., Alhaskawi A., Zhou H. et al. (2023) Imaging diagnosis in peripheral nerve injury. Frontiers in Neurol., 14: 1250808.
5. Zhu J., Hu Z., Luo Y. et al. (2024) Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Frontiers in endocrinol., 14: 1265372.
6. Martini R., Willison H. (2016) Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies? Glia, 64(4): 475–486.
7. Eid S.A., Rumora A.E., Beirowski B. et al. (2023) New perspectives in diabetic neuropathy. Neuron., 111(17): 2623–2641. doi.org/10.1016/j.neuron.2023.05.003.
8. Watson J.C., Dyck P.J. (2015) Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. Mayo Clin. Proc., 90(7): 940–951.
9. Hammi C., Yeung B. (2022) Neuropathy. In: StatPearls. Treasure Island: StatPearls Publ.
10. Huebner E.A., Strittmatter S.M. (2009) Axon regeneration in the peripheral and central nervous systems. Results Problю Cell Differ., 48: 339–351.
11. Allodi I., Udina E., Navarro X. (2012) Specificity of peripheral nerve regeneration: interactions at the axon level. Prog. Neurobiol., 98(1): 16–37.
12. Webber C., Zochodne D. (2010) The nerve regenerative microenvironment: early behavior and partnership of axons and Schwann cells. Exp. Neurol., 223(1): 51–59.
13. Ulrich H., Abbracchio M.P., Burnstock G. (2012) Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. Stem. Cell Rev. Rep., 8(3): 755–767. doi.org/10.1007/s12015-012-9372-9.
14. Menéndez-Méndez A., Díaz-Hernández J.I., Miras-Portugal M.T. (2015) The vesicular nucleotide transporter (VNUT) is involved in the extracellular ATP effect on neuronal differentiation. Purinergic Signal., 11(2): 239–249.
15. Leibinger M., Müller A., Gobrecht P. et al. (2013) Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death Dis., 4(4): e609.
16. Negrão L., Nunes P.; Portuguese Group for the Study of Peripheral Neuropathy (2016) Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies. Pain Manag., 6(1): 25–29.
17. Martiáñez T., Carrascal M., Lamarca A. et al. (2012) UTP affects the Schwannoma cell line proteome through P2Y receptors leading to cytoskeletal reorganisation. Proteomics, 12(1): 145–156. doi.org/10.1002/pmic.201100187.
18. Feng Y., Chen L., Luo Q. et al. (2018) Involvement of microRNA-146a in diabetic peripheral neuropathy through the regulation of inflammation. Drug Des. Devel. Ther., 17(12): 171–177. doi.org/10.2147/DDDT.S157109.
19. Boucher I., Kehasse A., Marcincin M. et al. (2011) Distinct activation of epidermal growth factor receptor by UTP contributes to epithelial cell wound repair. Am. J. Pathol., 178(3): 1092–1105. doi.org/10.1016/j.ajpath.2010.11.060.
20. Cansev M. (2006) Uridine and cytidine in the brain: their transport and utilization. Brain Res. Rev., 52(2): 389–397. doi.org/10.1016/j.brainresrev.2006.05.001.
21. Manhães M., Cesar M., Justo R. et al. (2017) The Role of Nucleotides in Glial Cells during Peripheral Nerve Trauma and Compressive Disorders [Internet]. Peripheral Nerve Regeneration — From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based Therapies Development. InTech. doi.org/10.5772/68068.
22. Nunes C.P., Scussel Jr.A.B. et al. (2013) Alcoholic polyneuropathy: clinical assessment of treatment outcomes following therapy with nucleotides and vitamin B12. Research in Neurology: An Int. J., 2013: 1–16. doi.org/10.5171/2013.208067.